
    
      Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to assess the LDL-C lowering
      efficacy at Week 12 of various doses of LIB003 administered subcutaneously (SC) every 4 weeks
      (Q4W) in patients with hypercholesterolemia on stable diet and oral LDL-C-lowering drug
      therapy.
    
  